← Leaderboards
Masato Yamamoto
University Of Minnesota
$9,316,402
Attributed
$10,790,145
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $880.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,790,145 · 9
By mechanism
R01$9,239,778 · 6
T32$1,200,202 · 1
R56$276,500 · 1
P30$73,665 · 1
Top collaborators
- Gregory J Beilman7 shared
- Julia Davydova5 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Rachel R Hardeman$3,148,680
- Julia Davydova$3,953,014
- Michele L Allen$11,384,036
- David H Ingbar$22,490,578
- Kelsey Elizabeth Johnson$1,040,824
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorCancer CellVirusMalignant Neoplasm Of PancreasNovel TherapeuticsCancer EtiologyOperative Surgical ProceduresMediatingCessation Of LifeUnresectableBaseTherapeutic EffectFiberAdenovirusesIn VivoOncolysisIn VitroMesothelinDiagnosisAntitumor EffectViralOncolyticNext Generation
Grant awards (39)
Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDAC$354,563
R01 · FY2025 · CA · contact PI
Training the Next Generation of Surgeon-Scientists in Pancreatology$213,165
T32 · FY2025 · DK · contact PI
Genetic Mechanisms$44,099
P30 · FY2025 · CA · contact PI
Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDAC$336,835
R01 · FY2024 · CA · contact PI
Training the Next Generation of Surgeon-Scientists in Pancreatology$129,188
T32 · FY2024 · DK · contact PI
Genetic Mechanisms$29,566
P30 · FY2024 · CA · contact PI
Advanced Oncolytic Adenovirus Enabling Systemic Therapy of PDAC$354,563
R01 · FY2023 · CA · contact PI
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$345,230
R01 · FY2023 · CA · contact PI
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$345,230
R01 · FY2022 · CA · contact PI
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$352,275
R01 · FY2021 · CA · contact PI
Training the Next Generation of Surgeon-Scientists in Pancreatology$185,137
T32 · FY2021 · DK · contact PI
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC$352,275
R01 · FY2020 · CA · contact PI
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$352,275
R01 · FY2020 · CA · contact PI
Training the Next Generation of Surgeon-Scientists in Pancreatology$175,723
T32 · FY2020 · DK · contact PI
Combination therapy with IFN expressing oncolytic adenovirus for pancreatic cancer$352,275
R01 · FY2019 · CA · contact PI
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC$341,706
R01 · FY2019 · CA · contact PI
Training the Next Generation of Surgeon-Scientists in Pancreatology$162,955
T32 · FY2019 · DK · contact PI
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC$351,132
R01 · FY2018 · CA · contact PI
Training the Next Generation of Surgeon-Scientists in Pancreatology$167,093
T32 · FY2018 · DK · contact PI
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC$348,844
R01 · FY2017 · CA · contact PI
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment$315,400
R01 · FY2017 · CA · contact PI
Training the Next Generation of Surgeon-Scientists in Pancreatology$166,941
T32 · FY2017 · DK · contact PI
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC$347,700
R01 · FY2016 · CA · contact PI
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment$315,400
R01 · FY2016 · CA · contact PI
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment$315,400
R01 · FY2015 · CA · contact PI
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment$305,938
R01 · FY2014 · CA · contact PI
Next Generation Oncolytic Adenovirus for Advanced Pancreatic Cancer Treatment$315,400
R01 · FY2013 · CA · contact PI
Enhanced CRAd for Pancreatic Cancer$270,363
R01 · FY2013 · CA · contact PI
Enhanced CRAd for Pancreatic Cancer$287,621
R01 · FY2012 · CA · contact PI
Enhanced CRAd for Pancreatic Cancer$287,621
R01 · FY2011 · CA · contact PI
Enhanced CRAd for Pancreatic Cancer$296,516
R01 · FY2010 · CA · contact PI
Enhanced CRAd for Pancreatic Cancer$307,285
R01 · FY2009 · CA · contact PI
Enhanced CRAd for Esophageal Adenocarcinoma$328,761
R01 · FY2007 · DK · contact PI
Enhanced CRAd for Pancreatic Cancer$276,500
R56 · FY2007 · CA · contact PI
Enhanced CRAd for Esophageal Adenocarcinoma$270,023
R01 · FY2006 · DK · contact PI
Enhanced CRAd for Esophageal Adenocarcinoma$58,738
R01 · FY2006 · DK · contact PI
Enhanced CRAd for Esophageal Adenocarcinoma$336,673
R01 · FY2005 · DK
Enhanced CRAd for Esophageal Adenocarcinoma$336,673
R01 · FY2004 · DK
Enhanced CRAd for Esophageal Adenocarcinoma$357,063
R01 · FY2003 · DK